Bulletin
Investor Alert

New York Markets After Hours

Topics

Science and Technology

2:34 a.m. Sept. 15, 2021 - By Tomi Kilgore
Procept BioRobotics upsized IPO prices above the expected range, valuing company at $1 billionProcept BioRobotics Corp. is set to go public Wednesday, as the California-based surgical robotics company's upsized initial public offering priced above the expected range at $25.00 per share. The company sold 6.56 million shares in the IPO to raise $163.9 million. Procept had previously expected to offer 5.5 million shares in the IPO, which was projected to price between $22 and $24 per share. The stock is expected to begin trading Wednesday on the Nasdaq under the ticker symbol "PRCT." With 41.21 million shares outstanding after the IPO, the pricing values Procept at $1.03 billion. BofA Securities and Goldman Sachs are the joint lead bookrunning managers. The company had recorded a net loss of $27.4 million on revenue of $15.7 million in the six months ended June 30, after a loss of $25.7 million on revenue of $2.4 million in the same period a year ago. The company is going public at a time that the Renaissance IPO ETF has gained 7.4% over the past three months while the S&P 500 has tacked on 4.6%.
4:01 a.m. July 28, 2021 - By Jaimy Lee
Pfizer shares limited data about its COVID-19 booster candidate, says it ups protection against the delta variantPfizer Inc. said Wednesday that a third dose of its COVID-19 vaccine likely provides further protection against the delta variant, which is more infectious and thought to be driving the recent surge in cases, hospitalizations, and deaths in the U.S. The drug maker announced the news as part of its , saying that an additional dose of its two-dose COVID-19 vaccine series produced neutralizing antibody titers against delta that are 5 times higher than getting two doses in younger people and 11 times higher than getting two doses in older people. Pfizer did not provide any additional information at this time. Pfizer's stock is up 14.3% so far this year, while the broader S&P 500 has gained 17.2%.
7:59 a.m. June 7, 2021 - By Joseph Walker
FDA approves Biogen’s Alzheimer’s drug, the first to slow the disease Biogen drug approved after facing doubts over whether it slows progression of memory-robbing diseaseThe first drug promising to slow the memory-robbing march of Alzheimer’s disease was approved by U.S. health regulators, a watershed after years of research and billions of dollars in investment.
9:32 a.m. May 25, 2021 - By Tomi Kilgore
Pieris stock rockets on record volume after Genentech collaboration valued at up to $1.4 billionShares of Pieris Pharmaceuticals Inc. rocketed 57.3% on massive volume in afternoon trading Tuesday, after the Boston-based biotechnology company announced a respiratory and ophthalmology collaboration with Roche Holding AG's Genentech that could be valued at more than $1.4 billion. Trading volume spiked to a record 205.7 million shares, enough to make the stock the most actively traded on major U.S. exchanges, and compared with the full-day average of about 576,200 shares, according to FactSet. The collaboration and license agreement with Genentech is to discover, develop and commercialize respiratory and ophthalmology therapies using Pieris's Anticalin technology. Under terms of the collaboration, Pieris will receive an upfront payment of $20 million, and is eligible to receive more than $1.4 billion in additional milestone payments plus royalties for commercialized programs. Pieris recorded revenue of $29.3 million in 2020, down from $46.3 million in 2019. Pieris' part in the collaboration is discovery research and early preclinical development of the programs, while Genentech will be responsible for investigational new drug (IND)-enabling activities, clinical development and commercialization. The stock has now gained 16.4% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 0.9% and the S&P 500 has advanced 11.8%.
3:52 a.m. May 4, 2021 - By Jaimy Lee
Bausch reports a $610 million loss in the first quarter of the yearShares of Bausch Health Cos. Inc. were down 2.3% in premarket trading on Tuesday after the company said it faced continued pressure on sales from the COVID-19 pandemic into the first quarter of this year. Bausch had a loss of $610 million, or $1.71 per share, in the first quarter of 2021, compared with a loss of $152 million, or 43 cents per share, in the same quarter a year ago. Bausch did not provide adjusted earnings per share for the quarter. The company reported $2.02 billion in sales for the first quarter of the year, up from $2.01 billion in the like quarter a year ago. The FactSet consensus was $2.05 billion. Much of Bausch's business continues to be affected by the pandemic, it said, citing declining sales of irritable bowel syndrome drug Xifaxin and lower sales of eye-care products for the quarter. Bausch said it still plans to move forward with spinning off the Bausch + Lomb eye-care business, which had $881 million in sales for the quarter, up from $875 million in the first quarter of 2020. Bausch's other business focuses on pharmaceuticals; it had $1.14 billion in sales, compared with $1.13 billion in the same quarter a year ago. Bausch's stock has gained 51.0% since the start of the year, while the S&P 500 is up 11.6%.
3:25 a.m. Feb. 25, 2021 - By Jaimy Lee
Moderna reports $570 million in revenue for first time driven by sales of COVID-19 vaccineShares of Moderna Inc. gained 2.2% in premarket trading on Thursday after the company reported half a million dollars in sales of its COVID-19 vaccine in the fourth quarter of last year. The company had a loss of $272,000, or 69 cents per share, in the fourth quarter of 2020, compared with a loss of $123,000, or 37 cents per share, in the same quarter a year ago. The FactSet consensus was for a loss of 34 cents. It had revenue of $570.7 million in the fourth quarter of last year, up from $14.1 million in the same quarter ago, as its COVID-19 vaccine began to be distributed in several countries around the world, including the U.S. The FactSet consensus was $279 million in revenue for the quarter. The vaccine is the first authorized product in the company's history. Moderna said it plans to produce at least 700 million doses of its vaccine in 2021, up from a previous low-end range estimate of 600 million, with a new goal of making 1.4 billion doses in 2022. The company said it has concluded enrollment in a clinical trial testing the COVID-19 vaccine in teens, and a Phase 2 trial for kids between the ages of 6 months and 11 year olds is also expected to begin in the "near-term." Moderna's stock has rallied 509.4% over the past 12 months, while the broader S&P 500 is up 21.7%.
6:28 a.m. Feb. 10, 2021 - By Tomi Kilgore
Pacific Biosciences stock rockets ahead of earnings, after Softbank makes $900 million investmentShares of Pacific Biosciences of California Inc. shot up 22.3% toward a record in morning trading Wednesday, ahead of the genetic analysis company's fourth-quarter report due out after the closing bell, after the announcement that Japan-based Softbank Group Corp. invested $900 million in the company. The stock has now soared 230.0% over the past three months and skyrocketed 1,051.7% over the past year. In comparison, the iShares Nasdaq Biotechnology ETF has advanced 39.7% over the past 12 months and the S&P 500 has gained 16.5%. The company said Softbank's investment was in the form of convertible senior notes, which will mature in February 2028, and will have an initial conversion price of $43.50, or 10% above Tuesday's closing price of $39.54. "We believe that PacBio's HiFi sequencing will be the de facto standard tool for population genomics fundamentally altering the practice of healthcare," said Akshay Naheta, chief executive of Softbank's SB Management. Separately, Pacific Biosciences is expected to report later fourth-quarter earnings 43 cents a share on revenue of $24.05 million, after breaking even on a per-share basis on revenue of $27.93 million, in the same period a year ago.
5:04 a.m. Jan. 29, 2021 - By Tomi Kilgore
Tesla stock gets second $1,000+ price target, from Argus ResearchThere are now two Wall Street analysts that have targets for Tesla Inc.'s stock of more than $1,000, after Argus Research's Bill Selesky boosted his target by 30% in the wake of the electric vehicle (EV) market leader's . The stock fell 0.6% in premarket trading Friday, after losing 5.4% over the past two days. Selesky reiterated his buy rating and raised his price target to $1,010 from $777. That would make him the second-most bullish on Tesla, of the 37 analysts surveyed by FactSet, behind only Oppenheimer's Colin Rusch, . Selesky said he expects EVs to account for an increasingly larger portion of auto sales, as lower costs for battery packs makes them more affordable to the average car buyer, and Tesla is the "undisputed leader" in the EV space. "We also believe that Tesla is well positioned to expand in the Chinese market and further believe that the incoming Biden Administration will offer rebates and new tax incentives to encourage consumers to buy EVs, which we think favors Tesla versus all the rest," Selesky wrote in a note to clients. The stock has soared 103.4% over the past 30 days through Thursday, while the S&P 500 has gained 14.4%.
8:39 a.m. Jan. 26, 2021 - By Jaimy Lee
J&J CEO: Expect Phase 3 results for its COVID-19 vaccine candidate early next weekJohnson & Johnson expects to share details from the Phase 3 clinical trial for its COVID-19 vaccine candidate "early next week," according to remarks made by CEO Alex Gorsky on Tuesday during an earnings call. J&J's stock was up 3.0% in trading on Tuesday afternoon. The company's experimental COVID-19 adenovirus-based vaccine is currently being tested in late-stage clinical trials, and results are being closely watched for several reasons, including that it's a single-dose vaccine and there are ongoing supply issues for doses of the BioNTech SE /Pfizer Inc. and Moderna Inc. vaccines in the U.S. (Both of the currently authorized coronavirus vaccines in the U.S. require two doses.) "We're certainly hopeful that you're going to see a durable and a sustainable and patent response, particularly from our [adenovirus-based] vector approach," Gorsky told investors, according to a FactSet transcript of the call. J&J's stock is up 15.3% over the past 12 months, while the S&P 500 has gained 17.0%.
8:37 a.m. Jan. 25, 2021 - By Jaimy Lee
J&J may share findings from Phase 3 vaccine trial this weekShares of Johnson & Johnson were up 0.9% in trading on Monday, as the company nears the anticipated disclosure of interim results from a late-stage clinical trial evaluating its single-dose COVID-19 vaccine candidate. J&J said in mid-December it expects to share findings from the Phase 3 trial by the end of January, which would it the third company testing coronavirus vaccines in the U.S. to announce results from a closely watched Phase 3 trial. The other two vaccines, developed by BioNTech SE /Pfizer Inc. and Moderna Inc. , are both mRNA-based vaccines that received emergency use authorization from the Food and Drug Administration in December. J&J said in December that it will file for emergency authorization for its experimental adenovirus-based vaccine in February if results are ready by the end of January. The company is expected to release its fourth-quarter and full-year earnings on Tuesday. J&J's stock has gained 10.9% over the past year, while the S&P 500 is up 15.6%.
8:34 a.m. Nov. 23, 2020 - By Tomi Kilgore
Ideanomics stock leads all Nasdaq gainers after doubling investment in electric-tractor makerShares of Ideanomics Inc. soared 64.9% in very active midday trading Monday, making them the biggest gainers on the Nasdaq Exchange, after the company focused on investing in disruptive technologies announced the doubling of its investment in California-based Solectrac Inc., which makes battery-powered electric tractors. Trading volume swelled to 189.4 million shares in recent trading, compared with the full-day average of about 11.7 million shares. Ideanomics said it invested an additional $1.3 million in Solectrac, which increases its ownership stake to 24%. Ideanomics had announced on Oct. 22 an investment of $1.3 million to buy the 14.7% stake in Solectrac. Ideanomics said the latest investment allows it to recognize its stake in Solectrac under the equity method of accounting under generally accepted accounting principles (GAAP). "We believe Solectrac has enormous potential and, given the uptick in both product inquiries and investment interest they are seeing, we exercised our rights to increase our stake so we can help Solectrac scale to meet anticipated market demand," said Chief Executive Alf Poor. The stock has now nearly tripled (up 196.8%) year to date, while the S&P 500 has gained 10.4%.
6:23 a.m. Nov. 20, 2020 - By Tomi Kilgore
Sotera Health stock set to start trading after IPO pricing valued company at more than $6 billionShares of Sotera Health Co. are set to start trading Friday, after the Ohio-based sterilization and lab-testing services provider's initial public offering priced at the high end of the expected range. The company said late Thursday that its 46.6 million-share offering priced at $23.00 a share, compared with , as the company raised $1.07 billion in the IPO. With 277.33 million shares outstanding after the IPO, the pricing values the company at $6.38 billion. The stock is expected to begin trading on the Nasdaq under the symbol "SHC." For the nine months through Sept. 30, the company recorded net income of $5.1 million on revenue of $601.3 million, after income of $7.1 million on revenue of $584.8 million in the same period a year ago. The company is going public on a day that the Renaissance IPO ETF is rising 0.9% in morning trading while the S&P 500 is falling 0.4%.
10:22 a.m. Nov. 10, 2020 - By Ciara Linnane
Coronavirus update: U.S. adds another 130,000 cases in a day: ‘This is what exponential math looks like,’ says expert Per capita new case numbers are highest in North Dakota, South Dakota, Iowa and Wisconsin, filling hospitals and raising concerns that systems will be overwhelmed The global tally of confirmed cases of the coronavirus illness COVID-19 climbed above 51 million on Tuesday with cases racing across the U.S. and Europe as more localities opted to impose restrictions on movement to curb the spread.
1:20 p.m. Nov. 6, 2020 - By Ciara Linnane
Coronavirus update: U.S. new cases jump 20% to record 121,200 in a single day; ‘We North Dakotans are in crisis,’ says doctor 13 states posted record case numbers on Thursday, including Illinois, Ohio, Indiana, Minnesota, Iowa, Oklahoma, Nebraska and North DakotaJust one day after the U.S. surpassed 100,000 new cases of the coronavirus illness COVID-19 in a singe day, it set a fresh record that was 20% higher, straining hospitals in areas of the Midwest and South as they struggle to cope with an influx of patients.
2:13 p.m. Nov. 3, 2020 - By Ciara Linnane
Coronavirus update: U.S. headed for ‘most deadly phase’ of pandemic, says Dr. Birx, contradicting Trump’s insistence it has rounded a corner ‘We are entering the most concerning and most deadly phase of this pandemic … leading to increasing mortality,’ Dr. Birx warnsThe U.S. death toll from the coronavirus illness COVID-19 climbed toward 232,000 on Tuesday as American voters headed to the poll to elect a president, and the head of the White House Task Force created to manage the pandemic issued a dire warning.
5:36 a.m. Oct. 31, 2020 - By Ciara Linnane
Coronavirus update: U.S. counts almost 100,000 cases in new one-day record; The Lancet says Trump pandemic response is ‘disastrous’ USA Today poll finds most Americans disapprove of Trump’s campaign rallies, prefer Biden’s more discreet approachThe U.S. death toll from the coronavirus illness COVID-19 headed toward 230,000 on Saturday and cases topped 9 million after more than 99,000 infections were counted in a record one-day tally, with infections climbing in all swing states just days ahead of the presidential election.
7:46 a.m. Oct. 29, 2020 - By Ciara Linnane
Coronavirus update: U.S. continues to set new case records as Trump remains insistent that U.S. has ‘rounded the corner’ New COVID-19 cases are rising in 47 states, and 27 states recorded 1,000 or more new diagnoses in the last 24 hoursThe U.S. death toll from the coronavirus illness COVID-19 edged closer to 228,000 on Thursday and more than 81,000 new infections were recorded in a single day, pushing the seven-day tally to record highs.
4:14 a.m. Oct. 29, 2020 - By Jaimy Lee
Moderna's stock is up as it says it is 'actively preparing' for launch of COVID-19 vaccineShares of Moderna Inc. were up 2.9% in premarket trading on Thursday after the company again reminded investors that the Phase 3 clinical trial for its COVID-19 vaccine candidate is fully enrolled as part of its third-quarter earnings announcement. It also said it is "actively preparing for the launch" of its COVID-19 vaccine. Moderna is a preclinical company, meaning it does not yet have an authorized or approved product available on the market. It is developing several mRNA-based vaccines, including one for the coronavirus. The company said its research and development expenses have nearly tripled to $344.5 million in the third quarter of 2020, primarily due to R&D costs for its experimental COVID-19 vaccine, compared with $119.6 million in the same quarter a year ago. Moderna said it plans to conduct two interim analyses for the late-stage trial of the vaccine. Moderna's stock has gained 236.1% so far this year, while the S&P 500 is up 1.2%.
3:27 a.m. Oct. 29, 2020 - By Ciara Linnane
Coronavirus update: Pandemic sets record case numbers across the U.S. as White House suggests the crisis is over U.S. has counted a record 500,000 new cases in the past week, and hospitals in isolated areas of the Midwest are rapidly fillingThe coronavirus pandemic continued to set records across the U.S. on Wednesday, even as the administration of President Donald Trump touted its first-term accomplishments in a news release that suggested it had ended the crisis that has cost more than 226,000 American lives and shows no signs of abating.
2:17 a.m. Oct. 28, 2020 - By Ciara Linnane
Coronavirus update: U.S. case tally tops 8.7 million and marks seven-day record, with more than 20 states seeing most new cases since start of the outbreak Dr. Birx says North Dakotans’ failure to wear face masks is ‘deeply unfortunate’ as the Dakotas suffer worst case numbers measured per capitaThe U.S. case tally for the coronavirus illness COVID-19 climbed above 8.7 million on Tuesday, with more than 20 states counting record numbers of new infections, as more business curfews were announced to combat the spread.
3:24 a.m. Oct. 27, 2020 - By Jaimy Lee
Pfizer cites $500 million impact in the third quarter as a result of the COVID-19 pandemicShares of Pfizer Inc. were up 0.1% in premarket trading on Tuesday after the drug maker missed sales expectations for the quarter. Pfizer had earnings of $2.2 billion, or 39 cents per share, in the third quarter of 2020, down from $7.7 billion, or $1.36 per share, in the same quarter a year ago. It had adjusted earnings per share of 72 cents for the quarter, against a FactSet consensus of 71 cents. The drug company's revenue fell 4% to $12.1 billion for the quarter, compared with $12.7 billion in the same quarter a year ago. The FactSet consensus was $12.3 billion. The company attributed an estimated unfavorable impact of $500 million for the quarter to the COVID-19 pandemic, citing lower demand for anti-infective products used in surgeries in China and disruptions in traditional prescribing patterns in the U.S. as people avoided going to to the doctor, including a 19% drop in sales of its smoking-cessation drug Chantix. The impact was offset to some degree by "strong performance" of its heart drugs, Vyndaqel and Vyndamax, and its biosimilars business. It did not disclose any additional details about its work to develop a COVID-19 vaccine with BioNTech . However, it did note that the Phase 2/3 clinical trial for the vaccine candidate had enrolled 42,000 participants as of Monday, and about 85% of the participants have received their second and final dose of the experimental vaccine. Pfizer adjusted its 2020 guidance for adjusted earning share to $2.88 to $2.93, from $2.85 to $2.95. Pfizer's stock is down 3.2% for the year, compared with the S&P 500 , which has gained 5.2%.
10:54 a.m. Oct. 23, 2020 - By Ciara Linnane
Coronavirus update: U.S. death toll tops 223,000; rural hospitals are filling and the Dakotas lead the nation by new infections South Dakota has six out of 10 of the hot spot counties identified by a New York Times tracker, while North Dakota hospitals are at 88% capacityThe U.S. death toll from the coronavirus illness COVID-19 rose above 223,000 on Friday, after the U.S. recorded its second-highest new daily case tally of more than 75,000 and data showed more than 40,000 people are hospitalized, stretching resources in many rural areas.
3:18 a.m. Oct. 23, 2020 - By Ciara Linnane
Coronavirus update: U.S. death toll tops 222,000 and President Trump criticizes media for constant coverage of crisis ‘All you hear is Covid, Covid, Covid, Covid, Covid, Covid, Covid, Covid, Covid, Covid, Covid,’ Trump tells rallyThe U.S. death toll from the coronavirus illness COVID-19 rose above 222,000 on Thursday, and President Donald Trump again falsely claimed the virus was disappearing and criticized the media for its constant coverage of the crisis.
2:08 a.m. Oct. 22, 2020 - By Ciara Linnane
Coronavirus update: CDC says nearly 300,000 excess American deaths have occurred during pandemic CDC study finds biggest percentage rise in excess deaths were in those aged 25 to 44, Blacks and Hispanics hit disproportionatelyThe U.S. death toll from the coronavirus illness COVID-19 rose above 221,000 on Wednesday, according to data aggregated by Johns Hopkins University, and the nation’s leading public health agency estimated that the pandemic has contributed to the deaths of almost 300,000 Americans, including fatalities that would not have happened without the virus.
10:38 a.m. Oct. 20, 2020 - By Ciara Linnane
Coronavirus update: Global case tally climbs to 40.6 million and WHO expert urges governments to look to regions that have succeeded in containing spread ‘The success countries in Asia had was their ability…to find the cases and the contacts, and do enough to start breaking the chains of transmission,’ says WHO’s Michael RyanThe number of confirmed cases of the coronavirus illness COVID-19 worldwide climbed to 40.6 million on Tuesday, amid continued rises in cases in Europe and the U.S., and a World Health Organization official urged governments to emulate actions taken in those regions that have succeeded in getting the deadly illness under control.
11:49 a.m. Oct. 15, 2020 - By Ciara Linnane
Coronavirus update: U.S. death toll tops 217,000; the magazine Nature becomes the latest science journal to blast Trump’s pandemic management Nature joins the New England Journal of Medicine, Scientific American and Lancet Oncology in criticizing Trump’s failings and endorsing Joe Biden for presidentThe U.S. death toll from the coronavirus illness COVID-19 climbed above 217,000 on Thursday, as Nature magazine became the latest scientific journal to sharply criticize President Donald Trump’s handling of the pandemic, and endorse rival, Democrat Joe Biden, for president.
10:45 a.m. Oct. 14, 2020 - By Ciara Linnane
Coronavirus update: U.S. death toll tops 216,000 as Midwest and Mountain West cases start to stretch hospital capacity In the last seven days, 16 states have added more new cases than at any other time since the beginning of the pandemic The U.S. death toll from the coronavirus illness COVID-19 rose above 216,000 on Wednesday, driven by a spike in new cases in the Midwest and Mountain West that are starting to fill hospital beds and squeeze health-care systems.
3:08 a.m. Oct. 13, 2020 - By Jaimy Lee
J&J's stock falls though third-quarter earnings beat expectationsShares of Johnson & Johnson were down 0.9% in premarket trading on Tuesday though the health care giant beat expectations for the quarter. It had net earnings of $3.5 billion, or $1.33 per share, in the third quarter of 2020, compared with $1.7 billion, or 66 cents per share, in the third quarter of 2019. Adjusted earnings per share for the quarter were $2.20, against a FactSet consensus of $1.98. The company had $21.2 billion in revenue for the quarter, up from $20.7 billion in the same period a year ago, against a FactSet consensus of $20.2 billion. The growth was driven primarily by J&J's pharmaceuticals business, which reported $11.4 billion in revenue for the third quarter, up from $10.8 billion in the same quarter last year. Its medical device business, which has been negatively impacted by delayed or canceled medical procedures and surgeries as a result of the COVID-19 pandemic, had $6.1 billion in revenue for the quarter, down from $6.4 billion in the same quarter a year ago. J&J raised its sales outlook for the year to $81.2 billion to $82.0 billion, with adjusted EPS of $7.95 to $8.05. It had previously said its 2020 adjusted EPS would be in the range of $7.75 to $7.95. that J&J had paused its late-stage study with 60,000 participants for its COVID-19 vaccine candidate over an unexplained illness in one of the 60,000 participants. J&J's stock is up 4.1% for the year, while the S&P 500 has gained 9.4%.
11:05 a.m. Oct. 8, 2020 - By Ciara Linnane
Coronavirus update: New England Journal of Medicine says Trump should be voted out over pandemic management as U.S. death toll tops 212,000 ‘When it comes to the response to the largest public health crisis of our time, our current political leaders have demonstrated that they are dangerously incompetent,’ say editors of prestigious medical journalThe U.S. death toll from the coronavirus illness COVID-19 moved above 212,000 on Thursday, as the editors of the prestigious New England Journal of Medicine sharply criticized the Trump administration’s handling of the pandemic.
4:10 a.m. Sept. 23, 2020 - By Tomi Kilgore
Tesla's stock falls, but Oppenheimer's Rusch says buy on weaknessShares of Tesla Inc. took a 5.8% premarket hit Wednesday, after investors apparently , but Oppenheimer analyst Colin Rusch was more upbeat, saying he would be "buyers on any near-term weakness." Rusch reiterated the outperform rating he's had on the stock for at least the past two years and kept his price target at $451. He said Tesla outlined a "robust reimagining of battery design, manufacturing and performance," including targeting a $25,000 vehicle in three years and a 20-times capacity increase by 2030. Rusch also noted that Tesla's 30% to 40% delivery growth guidance for 2020 is above consensus estimates. "We are impressed with the ambition of the endeavor and believe this roadmap charts ongoing technology and cost leadership for [Tesla] enabling sales into the entire LDV market," Rusch wrote in a note to clients. "While limited details may weigh on shares, we would be buyers on any near-term weakness." Tesla's stock has more than doubled (up 111.7%) over the past three months through Tuesday, while the S&P 500 has gained 5.9%.
Browse topics:

Filter results by

Location

Us (443)

Europe (90)

Asia Pacific (79)

Eu (66)

China (56)

Latin America (18)

Link to MarketWatch's Slice.